Are There Peptide Protocols for Perimenopausal Women?

Perimenopause does not begin with estrogen dropping. That is the common version of the story, and it gets the sequence wrong in a way that leads women to the wrong treatments in the wrong order.

Here is what actually happens.

Your ovaries have been releasing an egg roughly once a month for decades, and every time that egg releases, the follicle that held it collapses into a structure called the corpus luteum, which is a temporary gland that produces progesterone for the second half of your cycle. When perimenopause begins, ovulation becomes inconsistent. Some months you ovulate, some months you do not, and when you do not ovulate there is no corpus luteum, which means there is no progesterone. That is the first thing to go. Progesterone drops before estrogen does, and the gap between those two events can span years.

Estrogen does not simply decline alongside it. Research from Santoro and colleagues published in the Journal of Clinical Endocrinology and Metabolism in 2004 documented that estrogen during perimenopause becomes erratic, spiking higher than levels seen in a woman's twenties and then crashing and then spiking again, in a pattern that has nothing to do with her symptoms on any given day. So what you end up with is not a simple decline in both hormones. You end up with a broken ratio, where progesterone is low and estrogen is unpredictable, and that broken ratio is what drives the visceral fat accumulation, the disrupted sleep, the anxiety, and the changes in body composition that women notice even when nothing about their training or their diet has changed.

Understanding this sequence matters because it changes what you do first.

The instinct for many clinicians is to reach for estrogen. But if your ovaries are still producing estrogen unpredictably and you add more on top of that, you can amplify the erratic swings rather than stabilize them. The more logical starting point is progesterone, because that is the hormone that is actually deficient. A Phase III randomized controlled trial published in Scientific Reports by Prior and colleagues in 2023 found that oral micronized progesterone improved sleep quality and reduced night sweats compared to placebo, which means the progesterone deficiency is not just a hormonal technicality, it is the direct mechanism behind two of the most disruptive symptoms women experience in this phase.

The question of when to add estrogen has a practical anchor. Your doctor can measure something called anti-Mullerian hormone, which is a marker of how many viable follicles your ovaries still have and therefore how much unpredictable estrogen production is still happening. Research from the Penn Ovarian Aging Study, which followed 401 women over 14 years, found that AMH levels predict the timing of menopause with meaningful precision. When AMH is essentially undetectable and you have gone 12 consecutive months without a period, that is the clinical threshold for menopause, and that is typically when adding estrogen becomes appropriate because the erratic production from the ovaries has stopped.

Now, within that framework, peptides can play a real role. But the word "role" matters here, because they are working on symptoms and downstream systems, not on the hormonal deficit driving everything.

There are three systems worth targeting. The first is your metabolic system. The shift in the progesterone to estrogen ratio promotes fat storage, particularly visceral fat in the midsection, and it contributes to what some researchers describe as increased food noise, meaning the cognitive preoccupation with eating and appetite that makes dietary adherence harder. Peptides like tirzepatide, which acts on both GLP-1 and GIP receptors to reduce appetite and improve insulin signaling, or retatrutide, which adds a third receptor target and shows even stronger metabolic effects in early trial data, can help manage this. They are not correcting the hormonal cause, but they are working on a real downstream consequence.

The second system is sleep and anxiety. Progesterone itself has direct effects on GABA receptors in the brain, which is why its decline tends to produce anxiety and poor sleep alongside the hormonal symptoms. Peptides like Selank, which modulates the anxiolytic system without the dependency risk of benzodiazepines, and DSIP, which stands for delta sleep-inducing peptide and acts on sleep regulatory pathways, can help fill some of that gap. The evidence for these is less robust than for the metabolic peptides, and much of the mechanistic data comes from animal models or small human studies, so the degree of effect is harder to predict in any individual.

The third system is the growth hormone axis, and this is where the hormonal sequencing becomes most important to understand before you spend money on peptides.

Your pituitary gland releases growth hormone in pulses, and those pulses drive the liver to produce something called IGF-1, which is insulin-like growth factor 1, a signaling molecule that supports muscle repair, body composition, metabolic function, and tissue maintenance. Secretagogue peptides like tesamorelin or CJC-1295 work by amplifying those pituitary pulses, essentially giving the gland a louder signal to release more growth hormone.

The problem is that estrogen is one of the inputs that makes the pituitary sensitive to that signal in the first place.

A study by Shah and colleagues published in the Journal of Clinical Endocrinology and Metabolism in 2019 measured pulsatile growth hormone secretion in women with and without estradiol present. The difference was statistically significant at P equals 0.001. Without estrogen, the pituitary's response to growth hormone releasing hormone was significantly blunted. The signal goes in and the gland responds less. So if you add a growth hormone secretagogue during perimenopause before you have stabilized estrogen, you are paying for a louder signal going into a receiver that cannot hear it well.

This is the core sequencing principle, and it applies to all three peptide categories to varying degrees. Metabolic peptides will work regardless of hormone status because they act on peripheral receptors. Sleep and anxiety peptides will help but may underperform if progesterone deficiency is still actively destabilizing your sleep architecture. And growth hormone secretagogues will be measurably limited until estrogen levels are stable enough to restore pituitary sensitivity.

The peptides are a second layer. The hormones are the foundation, and building the second layer before the foundation is set is why some women try these protocols and feel little to nothing.

Getting the sequence right does not require a complicated protocol. It requires understanding that perimenopause is a progesterone deficiency first, an estrogen dysregulation second, and a downstream consequence of both those things third, and that the tools you reach for should match that order.

---

References

1. Santoro et al., 2004, Journal of Clinical Endocrinology & Metabolism — progesterone declines before estrogen, estrogen becomes erratic during perimenopause
2. Freeman et al., 2012, Journal of Clinical Endocrinology & Metabolism — AMH predicts menopause timing (Penn Ovarian Aging Study, 401 women, 14 years)
3. Prior, 2014, Facts, Views & Vision in ObGyn — progesterone as appropriate first-line therapy for perimenopause
4. Shah et al., 2019, Journal of Clinical Endocrinology & Metabolism — pulsatile GH secretion significantly blunted without estradiol (P = 0.001), estrogen potentiates pituitary GHRH response
5. Prior et al., 2023, Scientific Reports — Phase III RCT, oral micronized progesterone improved sleep quality and reduced night sweats vs placebo

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness